Eli Lilly Aims to Leverage GLP-1 Success for Future Acquisitions
Eli Lilly is capitalizing on the success of its GLP-1 drugs, Mounjaro and Zepbound, which saw sales increases of 125% and 80%, respectively, in Q1 2026. The company plans to use this financial windfall for acquisitions as it faces potential competition from Novo Nordisk's new Wegovy pill.
Topics: Eli Lilly GLP-1 drugs Mounjaro Novo Nordisk Wegovy Zepbound